Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
about
Melanized fungi in human diseasePosaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other ConditionsRhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodAccessing a small library of pluripotent 1,4,5-trisubstituted 1H-1,2,3-triazoles via diversity-oriented synthesis.Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infectionPharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Therapy of infections caused by dematiaceous fungi.Fungal CNS infections in patients with hematologic malignancy.Role of posaconazole in the management of oropharyngeal and esophageal candidiasisEvaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.Dematiaceous fungi.Combination antifungal therapy: the new frontier.Clinical pharmacology of antifungal agents in pediatric patients.Use of terbinafine in rare and refractory mycoses.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Antifungal agents--clinical pharmacokinetics and drug interactions.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Design and synthesis of new fluconazole analogues.Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.Posaconazole for the management of mucosal candidiasis.Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.Posaconazole (Noxafil): a new triazole antifungal agent.Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.Posaconazole in lung transplant recipients: use, tolerability, and efficacy.Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.Role of posaconazole in the treatment of oropharyngeal candidiasisEffectiveness of posaconazole in recalcitrant fungal keratitis resistant to conventional antifungal drugs.Synthesis and in vitro and in vivo antifungal activity of the hydroxy metabolites of saperconazole.[Candida glabrata : pathogenicity and therapy update].Liposomal amphotericin B and surgery as successful therapy for pulmonary Lichtheimia corymbifera zygomycosis in a pediatric patient with acute promyelocytic leukemia on antifungal prophylaxis with posaconazole.Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients.Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
P2860
Q24633163-BC3AF32E-02F3-47AD-B3E1-4F181A5340D9Q29399166-8F5EEA4A-2E49-47B0-BCD6-185B30B51DC6Q31033645-3CADDAC4-5163-4992-9722-C0E54C15F8C9Q34108484-F885C623-37AC-4BBF-9623-DEA0C2691979Q34243170-388440E3-A161-49A4-AE2A-DCB1AD010CA0Q34498982-310FB7C0-5B25-408C-916F-877CB96C8161Q34633796-0784F246-D12A-4593-AFF5-4962BFB555EFQ34680655-6B9CED00-C1C7-4B15-9908-443B5F161F04Q35647678-FE67E111-BCB8-41A0-92B1-1A219B0C0A6FQ36233517-7EAC8271-841C-4CFB-A397-471B129FA139Q36278069-B8DC60BD-29AA-4FE2-9D5A-35D03F97BD0EQ36642964-05320AEE-410F-441E-A5C9-8F80BC90C60CQ36714507-FE9ABE89-F825-482F-B564-3411E989B9F7Q36738130-3AB37673-0340-4CC7-BBE7-1E975C260CCFQ36895652-3DD61F73-9292-4E87-A288-B5BE8CDFDAA7Q36968140-C9C4DCB6-97C6-4743-8521-BC16419CABA2Q37071133-85348E4F-A964-40EF-B5E6-AB4F6EBA8173Q37115829-4FBEB30B-70AC-4592-93E9-71147AA7898AQ37159568-679D7457-10AB-4AC0-8FE2-A6660B78CDBFQ37404840-4D4F852B-4DF9-4726-B86A-256BD82ACF97Q37608276-EB1A6353-7797-4A92-A49C-072EDAEC0B4DQ37761047-A374E1A0-6172-4CAF-B426-363655DF5D43Q38681635-673D724C-4750-4B08-A644-0DD5B5A2D006Q38874757-AB16B4AD-E624-4D2F-958B-B140FF04B0FAQ39077404-E61F8E23-959E-4614-B114-7C0906CFA5E1Q40188971-F34AA8A5-88F8-4C57-9CD0-33E029CA11CCQ40323166-3946D7E4-098E-4D65-8123-B383FE3BFA39Q40413232-83EE882F-4EDF-4F9A-A4ED-12959FA9F55CQ40452729-3F9B002F-7786-4DDE-811E-852640CEF13AQ40517272-31F73990-C1AE-4EB5-8537-D0AF667E0369Q40577292-0A905B33-47A0-4961-B791-6B3715C6ADF5Q40827808-DA7DC4F4-F569-4C5A-AD29-1883C3B3AEA9Q40841377-5D3FD306-7A4F-469C-80E6-674F63CF403FQ41842051-658560B6-87D4-4518-A7C9-638EA1B8D93FQ41868240-91173F9D-2547-46F8-A4B6-6B81DB28B312Q43105019-DF8E112D-FFCE-4ABF-B7EB-FCA4F28F35E8Q44147815-A6E6FD49-EC49-4830-BF82-D02725F543EFQ45807101-5CA168EB-F598-47DE-98AB-80FE54E56733Q46684813-B5823D81-A6EF-422E-A3EF-0811A154ABC7Q46840248-E6E611A2-45AF-43E4-8583-A90BC44E2931
P2860
Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Posaconazole: a potent, extend ...... of serious fungal infections.
@ast
Posaconazole: a potent, extend ...... of serious fungal infections.
@en
type
label
Posaconazole: a potent, extend ...... of serious fungal infections.
@ast
Posaconazole: a potent, extend ...... of serious fungal infections.
@en
prefLabel
Posaconazole: a potent, extend ...... of serious fungal infections.
@ast
Posaconazole: a potent, extend ...... of serious fungal infections.
@en
P1476
Posaconazole: a potent, extend ...... t of serious fungal infections
@en
P2093
R Herbrecht
P304
P356
10.1111/J.1368-5031.2004.00167.X
P577
2004-06-01T00:00:00Z